Últimas noticias sobre Currenc Group (NASDAQ:CURR) Bolsa

Currenc Group

Currenc Group Inc is a is a fintech pioneer dedicated to transforming financial services through artificial intelligence (AI). It empowers financial institutions with comprehensive AI solutions, including the SEAMLESS AI Call Centre and other AI-powered tools designed to reduce costs, increase efficiency and boost customer satisfaction. The Company's digital remittance platform also enables e-wallets, remittance companies, and corporations to provide real-time, 24/7 payment services, advancing financial access across underserved communities.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEMD

APCX

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

DALN

DSGN

ELAB

KULR

LITM

MESO

NVNI

PTPI

QNTM

SGMO

SLXN

VRAX

Acciones de Sangamo Therapeutics suben un 19,5% tras un nuevo acuerdo. Descubre los mayores ganadores y perdedores de hoy.

Acciones de Sangamo Therapeutics (SGMO) suben alrededor de un 20%; 20 acciones que se mueven en el premercado

Currenc Group Inc

CURRYS PLC U/ADR by CURRYS PLC

CURRENCY EXCHANGE INTL CP by Currency Exchange International Corp

Currency Exchange International Corp

Current Energy and Renewables Corp

CURRENT WATER TECHS INC by Current Water Technologies Inc.

Current Water Technologies Inc

Currys PLC

Chardan Capital analyst Daniil Gataulin maintains uniQure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) with a Buy and maintains $38 price target.

Price Target

Analyst Ratings

QURE

Chardan Capital Maintains Buy on uniQure, Maintains $38 Price Target

Chatham Lodging (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLDT#NYSE">CLDT</a>) is looking for Q2 FFO of $0.32-$0.36 vs $0.36 analyst estimate. sees sales of $79.000 million-$80.200 million vs $82.30 million analyst estimate.

Guidance

CLDT

Chatham Lodging Sees Q2 AFFO $0.32-$0.36 vs $0.36 Est; Sees Sales $79.000M-$80.200M vs $82.30M Est

Duke Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) affirms FY2025 Adj EPS guidance from $6.17-$6.42 to $6.17-$6.42 vs $6.32 analyst estimate..

Duke Energy Affirms FY2025 Adj EPS Guidance of $6.17-$6.42 vs $6.32 Est

Chatham Lodging (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLDT#NYSE">CLDT</a>) lowers FY2025 FFO guidance from $1.01-$1.11 to $0.95-$1.03 vs $1.05 analyst estimate. Lowers FY2025 sales outlook from $298.00 million-$305.00 million to $295.00 million-$298.00 million vs $306.35 million estimate.

Chatham Lodging Lowers FY2025 AFFO Guidance From $1.01-$1.11 to $0.95-$1.03 Vs $1.05 Est; Lowers Sales Guidance From $298.00M-$305.00M To $295.00M-$298.00M Vs $306.35M Est

Earnings

Earnings Beats

Duke Energy Q1 Adj. EPS $1.76 Beats $1.60 Estimate, Total Operating Revenues $8.25B Beat $8.06B Estimate

Babcock &amp; Wilcox Enterprises, Inc. ("B&amp;W" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BW#NYSE">BW</a>) announced it has sold the majority of the assets of its Denmark-based Babcock &amp; Wilcox A/S (B&amp;W A/S) subsidiary to Kanadevia Inova Denmark A/S (Kanadevia Inova) for $20 million, a portion of which will be used for the deployment of B&amp;W's BrightLoop&#x2122; hydrogen production and carbon capture facility in Massillon, Ohio. Kanadevia Inova is a global greentech leader, pioneering innovative solutions for the energy transition and circular economy.

Babcock & Wilcox Sells Majority Of Its Denmark-Based Subsidiary Assets To Kanadevia Inova For $20M

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) reportedly has over 10,000 units of the Cybertruck in its domestic inventory as the company grapples with poor sales and an aging line-up of vehicles.
What Happened: Elon Musk's EV giant could be sitting on over $800 million worth of Cybertruck inventory, according <a href="https://electrek.co/2025/05/05/tesla-cybertruck-inventory-skyrockets-to-record-high/">to</a> an Electrek report on Monday.
The report suggests that despite there not being a way to track Tesla units in the U.S., listings of Tesla models can be tracked. The report also outlines how Tesla may publish a single listing for multiple vehicles at the same location with the same features, which could indicate the company has more inventory.
Tesla did not immediately respond to<a href="http://pro.benzinga.com"> Benzinga's</a> request for comment.
Why It Matters: Tesla has been grappling with declining sales figures in the U.S. as well as Europe. The company's market share in Europe currently stands at 2%, down from 2.9% last year, and it registered 571 units sold in Spain, according to experts.
Cybertruck also went through a <a href="https://www.benzinga.com/news/25/04/44967503/cybertruck-gets-a-down-to-earth-redesign-as-tesla-shifts-to-traditional-pickup-marketing-amid-poor-s">shift in marketing strategy</a>, which positions the vehicle as a capable, rugged pickup truck and expands on its utilitarian quotient. The company also released a <a href="https://www.benzinga.com/markets/equities/25/04/44755221/tesla-unveils-new-cybertruck-long-range-trim-with-a-362-mile-range-and-reduced-features">cheaper, RWD variant </a>of the Cybertruck to appeal to a wider customer base.
Tesla's new <a href="https://www.benzinga.com/tech/25/04/44857987/tesla-experiences-151-decline-in-new-vehicle-registrations-in-california-report">vehicle registrations </a>also fell in California, and the company's profits declined by over 71% YoY. This comes at a time when the company was reportedly exploring <a href="https://www.benzinga.com/25/04/45124373/tesla-board-explored-replacing-elon-musk-as-tesla-ceo-a-month-ago-report">a future without Musk</a>, which both the billionaire as well as the company have categorically denied.
Price Action: TSLA currently trades for $280.26 on the NASDAQ, according to<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro data</a>.
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/05/45214525/gary-black-flags-47-projected-drop-in-teslas-april-europe-sales-predicts-6-decline-in-2025-deliveries">Gary Black Flags 47% Projected Drop In Tesla&#8217;s April Europe Sales, Predicts 6% Decline In 2025 Deliveries</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

General

TSLA

Tesla Has Over 10,000 Units Of Unsold Cybertrucks In Its US Inventory Amid Poor Sales: Report

PINC

Premier Raises FY25 Adj EPS Guidance From $1.26 - $1.34 To $1.37 - $1.43 Vs. $1.29 Est.

SEAT

Due To Uncertainty Across The Global Economy, Vivid Seats Is Suspending Guidance For The Year Ending December 31, 2025

AG Mortgage Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MITT#NYSE">MITT</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.17 by 23.53 percent. This is unchanged from the same period last year.

MITT

AG Mortgage Investment Q1 Adj. EPS $0.21 Beats $0.17 Estimate

IDEAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>) reported quarterly losses of $(0.82) per share which missed the analyst consensus estimate of $(0.67) by 22.39 percent. This is a 54.72 percent decrease over losses of $(0.53) per share from the same period last year.

Earnings Misses

IDYA

IDEAYA Biosciences Q1 EPS $(0.82) Misses $(0.67) Estimate

Premier Updates FY25 Net Revenue Excluding Contigo Health Outlook From $940B - $1.01B to $955M - $995M

Buybacks

Chatham Lodging Trust Board Approves First-Ever $25M Share Buyback Program With No Time Limit

Chardan Capital analyst Geulah Livshits maintains Immuneering (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) with a Buy and maintains $13 price target.

IMRX

Chardan Capital Maintains Buy on Immuneering, Maintains $13 Price Target

2025 Financial Outlook Given the uncertainty in industry production caused by the evolving tariff environment, we are not reaffirming&nbsp;our 2025 financial outlook at this time. We remain confident in delivering the operating performance commitments for 2025 that we highlighted in our February 2025 earnings call. We intend to provide updates as visibility on industry production improves.

Lear Not Reaffirming 2025 Financial Outlook Given The Uncertainty In Industry Production Caused By Evolving Tariff Environment

Aramark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARMK#NYSE">ARMK</a>) affirms FY2025 Adj EPS guidance from $1.91-$1.98 to $1.91-$1.98 vs $1.91 analyst estimate..

ARMK

Aramark Affirms FY2025 Adj EPS Guidance of $1.91-$1.98 vs $1.91 Est

Premier (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PINC#NASDAQ">PINC</a>) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.30 by 46.67 percent. This is a 20 percent decrease over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $261.38 million which beat the analyst consensus estimate of $240.45 million by 8.71 percent. This is a 23.71 percent decrease over sales of $342.60 million the same period last year.

Premier Q3 Adj. EPS $0.44 Beats $0.30 Estimate, Sales $261.38M Beat $240.45M Estimate

Chatham Lodging (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLDT#NYSE">CLDT</a>) reported quarterly earnings of $0.14 per share which met the analyst consensus estimate. This is a 12.5 percent decrease over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $68.64 million which beat the analyst consensus estimate of $68.34 million by 0.43 percent. This is a 0.28 percent increase over sales of $68.44 million the same period last year.

Chatham Lodging Q1 FFO $0.14, Inline, Sales $68.64M Beat $68.34M Estimate

Vivid Seats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEAT#NASDAQ">SEAT</a>) reported quarterly sales of $164.02 million which missed the analyst consensus estimate of $169.71 million by 3.35 percent. This is a 14.06 percent decrease over sales of $190.85 million the same period last year.

Vivid Seats Q1 Sales $164.02M Miss $169.71M Estimate

Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) is looking for Q2 Adj EPS of $0.19-$0.32 vs $0.42 analyst estimate. sees sales of $270.000 million-$280.000 million vs $278.32 million analyst estimate.

OMCL

Omnicell Sees Q2 Adj EPS $0.19-$0.32 vs $0.42 Est; Sees Sales $270.000M-$280.000M vs $278.32M Est

Press Releases

Biotech Breakthroughs: Sana Biotechnology (NASDAQ: SANA) Type 1 Diabetes, CS Diagnostics (OTCQB: CSDX) Cancer Therapy – CURR, TPET, PRSO, PNPN.V, EONR – Plus More Stocks Under $2 Inside See Now!

Comments

Currenc Group

Noticias

Últimas noticias sobre Currenc Group (NASDAQ:CURR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL